A Type 2 diabetes drug can now help in reducing liver fat in non-alcoholic fatty liver disease (NAFLD) patients. Empagliflozin is the drug that helps decrease the buildup of fat in the liver.
Study Says Consuming Probiotics Reduce Liver Fat
Consuming probiotics for a month helps in diminishing fat accumulation in the liver finds new study.
Consuming probiotics for a month helps in diminishing fat accumulation in the liver finds new study.
‘Empagliflozin is the diabetic drug that can help decrease the buildup of fat in the liver.’
The middle-aged adults who received empagliflozin showed an average 16.2 to 11.3 percent decrease in liver fat post 20 weeks of treatment. On the other hand, the control group showed only a minimal decrease from 16.4 to 15.6 percent, the findings revealed.
"Despite the fact that NASH may progress to cirrhosis of the liver and liver cancer, there are no approved medications for treating NASH or NAFLD, and agents like metformin, pioglitazone, and Vitamin E have had limited success in reducing liver fat," said Ambrish Mithal, Chair of the Division of Endocrinology and Diabetes at Medanta The Medicity Hospital, Gurugram.
Liver Fat Maintains Sugar Levels in Blood, Says Animal Study
Mice in whom an enzyme called histone deacetylase 3 (HDAC3) is deleted, have massively fatty livers, but lower blood sugar, a new study has revealed.
Mice in whom an enzyme called histone deacetylase 3 (HDAC3) is deleted, have massively fatty livers, but lower blood sugar, a new study has revealed.
Previous studies had established the potential of the diabetes drug empagliflozin in decreasing liver fat in rodents with a buildup of fat in the liver.
Advertisements
Regular Exercise Reduces Liver Fat, Improves Non-Alcoholic Fatty Liver Disease
A short, moderate and daily exercise regimen, regardless of volume or intensity, benefits obese and overweight adults who have non-alcoholic fatty liver disease.
A short, moderate and daily exercise regimen, regardless of volume or intensity, benefits obese and overweight adults who have non-alcoholic fatty liver disease.
In the trial, the team included patients who were 40 years or older and had Type 2 diabetes and NAFLD.
Advertisements
Gastrointestinal Hormones may Help Ease Symptoms of Liver Diseases
The gastrointestinal hormone can measurably improve the symptoms of non-alcoholic fatty liver diseases, finds a new study. The treatment significantly reduced liver fat in liver diseases.
The gastrointestinal hormone can measurably improve the symptoms of non-alcoholic fatty liver diseases, finds a new study. The treatment significantly reduced liver fat in liver diseases.
Empagliflozin was approved by the US Food and Drug Administration in 2014 for adults with Type 2 diabetes.
It primarily acts by increasing glucose excretion through the urine, thereby reducing blood glucose levels and body weight.
Source-IANS
